IOVA Quote, Financials, Valuation and Earnings

Electromed has a net margin of -106.6% compared to Iovance Biotherapeutics's net margin of 12.11%. Iovance Biotherapeutics's return on equity of -52.91% beat Electromed's return on equity of 15.91%.

Iovance Biotherapeutics has a consensus price target of $19.54, signalling upside risk potential of 448.83%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 50.71%. Given that Iovance Biotherapeutics has higher upside potential than Electromed, analysts believe Iovance Biotherapeutics is more attractive than Electromed.

Iovance Biotherapeutics has a beta of 0.931, which suggesting that the stock is 6.856% less volatile than S&P 500. In comparison Electromed has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.696%.

Iovance Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Iovance Biotherapeutics pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Iovance Biotherapeutics quarterly revenues are $73.7M, which are larger than Electromed quarterly revenues of $16.3M. Iovance Biotherapeutics's net income of -$78.6M is lower than Electromed's net income of $2M. Notably, Iovance Biotherapeutics's price-to-earnings ratio is -- while Electromed's PE ratio is 32.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iovance Biotherapeutics is 6.29x versus 3.69x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -106.6% compared to Iovance Biotherapeutics's net margin of -1226.82%. Iovance Biotherapeutics's return on equity of -52.91% beat VolitionRX's return on equity of --.

Iovance Biotherapeutics has a consensus price target of $19.54, signalling upside risk potential of 448.83%. On the other hand VolitionRX has an analysts' consensus of $3.37 which suggests that it could grow by 505.63%. Given that VolitionRX has higher upside potential than Iovance Biotherapeutics, analysts believe VolitionRX is more attractive than Iovance Biotherapeutics.

Iovance Biotherapeutics has a beta of 0.931, which suggesting that the stock is 6.856% less volatile than S&P 500. In comparison VolitionRX has a beta of 1.092, suggesting its more volatile than the S&P 500 by 9.182%.

Iovance Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Iovance Biotherapeutics pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

Iovance Biotherapeutics quarterly revenues are $73.7M, which are larger than VolitionRX quarterly revenues of $474.5K. Iovance Biotherapeutics's net income of -$78.6M is lower than VolitionRX's net income of -$5.8M. Notably, Iovance Biotherapeutics's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iovance Biotherapeutics is 6.29x versus 35.95x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Viatris has a net margin of -106.6% compared to Iovance Biotherapeutics's net margin of -14.64%. Iovance Biotherapeutics's return on equity of -52.91% beat Viatris's return on equity of -3.22%.

Iovance Biotherapeutics has a consensus price target of $19.54, signalling upside risk potential of 448.83%. On the other hand Viatris has an analysts' consensus of $11.7625 which suggests that it could grow by 24.87%. Given that Iovance Biotherapeutics has higher upside potential than Viatris, analysts believe Iovance Biotherapeutics is more attractive than Viatris.

Iovance Biotherapeutics has a beta of 0.931, which suggesting that the stock is 6.856% less volatile than S&P 500. In comparison Viatris has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.819%.

Iovance Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viatris offers a yield of 5.1% to investors and pays a quarterly dividend of $0.12 per share. Iovance Biotherapeutics pays -- of its earnings as a dividend. Viatris pays out -90.63% of its earnings as a dividend.

Iovance Biotherapeutics quarterly revenues are $73.7M, which are smaller than Viatris quarterly revenues of $3.5B. Iovance Biotherapeutics's net income of -$78.6M is higher than Viatris's net income of -$516.5M. Notably, Iovance Biotherapeutics's price-to-earnings ratio is -- while Viatris's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iovance Biotherapeutics is 6.29x versus 0.77x for Viatris. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -106.6% compared to Iovance Biotherapeutics's net margin of -10.04%. Iovance Biotherapeutics's return on equity of -52.91% beat Xtant Medical Holdings's return on equity of -35.34%.

Iovance Biotherapeutics has a consensus price target of $19.54, signalling upside risk potential of 448.83%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 264.58%. Given that Iovance Biotherapeutics has higher upside potential than Xtant Medical Holdings, analysts believe Iovance Biotherapeutics is more attractive than Xtant Medical Holdings.

Iovance Biotherapeutics has a beta of 0.931, which suggesting that the stock is 6.856% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.747%.

Iovance Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Iovance Biotherapeutics pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Iovance Biotherapeutics quarterly revenues are $73.7M, which are larger than Xtant Medical Holdings quarterly revenues of $31.5M. Iovance Biotherapeutics's net income of -$78.6M is lower than Xtant Medical Holdings's net income of -$3.2M. Notably, Iovance Biotherapeutics's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iovance Biotherapeutics is 6.29x versus 0.55x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.